In:
International Journal of STD & AIDS, SAGE Publications, Vol. 16, No. 12 ( 2005-12-01), p. 807-810
Abstract:
To analyse if a four-drug combination including two protease inhibitors (PIs) accelerates viral decay and suppression as compared with standard triple therapy in heavily immunosuppressed HIV-1 infected patients, an open label clinical trial was designed. PIs naive patients receiving their first highly active antiretroviral therapy were included if their CD4 cell count was lower than 200/mm 3 and their HIV viral load (VL) 〉 100,000 RNA copies/mL. Every patient received two analogues and was randomized in two groups receiving either one PI (saquinavir soft gel capsule) or two PIs (saquinavir + nelfinavir). Viral efficacy (VL 〈 50), time to reach VL 〈 50, viral clearance rate constant and plasmatic elimination half-life were determined. In all, 30 patients were enrolled. No viral variable was significatively improved by the four-drug combination in the short term. No clinical benefit should be expected with a four-drug (two PIs) regimen in patients with low CD4 + cell count and high VL.
Type of Medium:
Online Resource
ISSN:
0956-4624
,
1758-1052
DOI:
10.1258/095646205774988082
Language:
English
Publisher:
SAGE Publications
Publication Date:
2005
detail.hit.zdb_id:
2009782-7
Permalink